A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

NCT05508867 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

203

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

BIOLOGICAL: favezelimab/pembrolizumab
DRUG: bendamustine
DRUG: gemcitabine

Sponsor

Merck Sharp & Dohme LLC